William Blair analyst Matt Phipps downgraded Chinook Therapeutics (KDNY) to Market Perform from Outperform without a price target entered into an agreement and plan of merger with Novartis (NVS) pursuant to which Novartis will acquire Chinook for $40 per share in cash, or a total of $3.2B. The firm views the deal as a “great outcome” for Chinook investors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KDNY:
- Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
- Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease
- KDNY Upcoming Earnings Report: What to Expect?
- Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress